Osimertinib, a third-generation EGFR-TKI, strongly inhibited H1975 cell proliferation but marginally affected cell proliferation in the lung cancer cell lines with acquired EGFR-TKI resistance (HCC827 GR, H1993 ER, and H292 ER) (Figure 1(b)). This evidence concerns the gene EGFR and lung cancer.